** Shares of cancer diagnostic test maker Grail GRAL.O fall 18.8% to $34.81 in extended trading
** Company's Q1 revenue of $31.8 million misses analysts' average expectation of $35.2 million, according to data compiled by LSEG
** GRAL reports quarterly loss of $3.10/shr, vs analysts' average estimate of $4.09/shr
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。